XBiotech Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 15, 2022 and accepted by EDGAR at Mar 15, 2022, 17:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $18.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $5.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2021-01-01 to 2021-12-31 | $12.6m | us-gaap:GrossProfit |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $28.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-10-01 to 2021-12-31 | −$7.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2021-01-01 to 2021-12-31 | −$25.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2021-01-01 to 2021-12-31 | −$8.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-10-01 to 2021-12-31 | −$6.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | −$17.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-10-01 to 2021-12-31 | −$0.21 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | −$0.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | −$0.58 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 30,043,380 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | $69.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $3.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2021-01-01 to 2021-12-31 | $75.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-12-31 | $237.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $246.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $275.2m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $3.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $5.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $269.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001171843-22-001904. Last ingested by Listed: Oct 26, 2026, 09:40 ET. Listed shows no prices and gives no investment advice.